Shots:

• The Novel START study results involve assessing of Symbicort Turbuhaler (prn) vs Albuterol (prn) or Budesonide (ICS maintenance treatment) + albuterol (prn) in 668 patients with mild asthma aged 18-75 yrs. across Australia- Italy- New Zealand and the UK
• The Novel START study results: 51% reduction in the rate of annual asthma exacerbation compared to albuterol (0.195 vs 0.400 /patient/year); asthma exacerbation compared to budesonide + albuterol (0.195 vs 0.175/patient/year)
• Albuterol is a short-acting beta2-agonist (SABA) reliever while budesonide is a low-dose inhaled corticosteroid (ICS) maintenance therapy. Symbicort is a combination therapy of budesonide and formoterol and its Turbuhaler device is approved as an anti-inflammatory reliever for mild asthma in Brazil & Russia

Ref: AstraZeneca | Image: AstraZeneca